Indian F&O data, and the evidence about what not to trade · educational
SUNPHARMA · Healthcare
1M / 3M / 1Y
-3.0% / +5.1% / +13.9%
Traded value (60d med)
₹335 cr
Days in F&O ban since 2020
0
Futures OI / 1d change
15.4M / -0.2M
ATM implied vol
14% (vs 21% realized)
📜 Results-day history
Typical move 1.5% · up on the day 44% of 27 events · moved 4%+ in 7% · worst -4.3% / best +6.9%
| Reaction day | Move | Open gap | Next 5d | Announced |
|---|
| 2026-07-24 | -0.7% | -0.5% | +2.5% | during mkt |
| 2026-04-29 | +1.8% | +0.5% | +4.0% | after close |
| 2026-01-21 | -0.1% | +1.4% | -0.1% | during mkt |
| 2025-10-30 | -0.7% | -0.0% | -1.0% | after close |
| 2025-07-23 | +0.3% | +0.0% | +3.0% | after close |
| 2025-04-30 | +1.5% | +0.2% | -3.6% | after close |
| 2025-02-03 | -0.2% | +2.2% | -0.5% | after close |
| 2024-10-29 | -1.6% | +1.0% | -3.6% | after close |
Educational data reference: NOT investment advice. Historical statistics do not predict future results. We are not SEBI-registered advisers. All data from NSE public sources; figures may contain errors. Trading, especially leveraged F&O, can cause significant losses.